Ovid Therapeutics Inc - OVID STOCK NEWS

Ovid Therapeutics (NASDAQ: OVID) reported its Q4 and full-year 2024 financial results, highlighting key pipeline developments and organizational updates. The company ended 2024 with $53.1 million in cash and equivalents, expected to fund operations into H2 2026.

Key developments include: appointment of Dr. Stelios Papadopolous to the Board of Directors; anticipated topline results from OV329's Phase 1 study in Q3 2025; and initiation of first-in-human study for OV350 in Q1 2025. The company reported full-year 2024 revenues of $566,000 and a net loss of $26.4 million ($0.37 per share).

Pipeline updates include:

• OV329: Phase 1 study progressing with no serious adverse events reported
• OV350: First KCC2 direct activator initiated human trials
• OV4071: First oral KCC2 activator targeting human studies in Q2 2026
• OV888/GV101: Phase 2 proof-of-concept study paused for strategic evaluation

Ovid Therapeutics (Nasdaq: OVID) has appointed Dr. Stelios Papadopoulos to its Board of Directors. Dr. Papadopoulos, a renowned scientist, investor, and entrepreneur with over four decades of biotechnology experience, will serve on the company's Audit and Compensation Committees.

The appointment comes at a strategic time as Ovid advances its pipeline, including novel KCC2 direct activators and OV329 epilepsy program, focusing on developing small-molecule medicines for brain conditions with significant unmet need.

Dr. Papadopoulos brings extensive experience from his roles at Cowen & Co., PaineWebber, and academic positions. He currently serves as Chairman of Exelixis and Regulus Therapeutics, and was previously Chairman of Biogen. He holds an MS in physics, PhD in biophysics, and MBA in finance from New York University.

Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company focused on developing medicines for brain conditions, has announced its participation in the TD Cowen 45th Annual Health Care Conference. Meg Alexander, President and Chief Operating Officer, will deliver a presentation on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, Massachusetts.

Investors and interested parties can access the live webcast through the Events & Presentations section at investors.ovidrx.com. A replay will remain available on the company's website for approximately 30 days after the presentation.

Ovid Therapeutics (Nasdaq: OVID), a biopharmaceutical company focused on developing medicines for brain conditions, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will deliver a virtual presentation on Wednesday, February 12, 2025, at 4:00 p.m. ET.

Interested parties can access the live webcast through the Events & Presentations section on the company's investor website at investors.ovidrx.com. For those unable to attend the live session, an archived replay will be made available on the company's website after the presentation.

Ovid Therapeutics (Nasdaq: OVID) announced the presentation of four posters at the 2024 American Epilepsy Society Annual Meeting in Los Angeles, highlighting their pipeline programs targeting neuronal hyperexcitability. The presentations focus on two key compounds: OV329, a next-generation GABA aminotransferase inhibitor, and OV350, a KCC2 direct activator.

The research demonstrates OV329's improved safety profile and lack of ocular accumulation compared to vigabatrin, along with its effectiveness in elevating GABA and suppressing seizures. Studies also show OV350's potential in treating nerve agent-induced benzodiazepine-resistant refractory status epilepticus. The company aims to be the first to study a KCC2 direct activator in humans next year.

Ovid Therapeutics reported Q3 2024 financial results and business updates. The company's Phase 1 SAD/MAD study of OV329 is progressing with plans to expand dosing opportunities. A regulatory application for OV350 Phase 1 trial is expected in Q4 2024. The company has paused Phase 2 study of OV888/GV101 to evaluate competitor trial insights. Financial position shows $62.7 million in cash and marketable securities, expected to support operations into H2 2026. Q3 results include revenue of $173,000, R&D expenses of $7.9 million, and a net loss of $14.0 million ($0.20 per share).

Ovid Therapeutics (Nasdaq: OVID) has announced an investor event called KCC2 Download Day scheduled for November 13, 2024, from 9:30 to 11:30 am ET at their New York headquarters. The event will focus on their portfolio of direct potassium chloride co-transporter 2 (KCC2) activators, including updates on OV350, their lead program.

Three distinguished speakers will present: Dr. Jeffrey Noebels from Baylor College of Medicine, Dr. Karl Kieburtz from University of Rochester School of Medicine, and Dr. Stephen Moss from Tufts University. The event will be available via webcast, and in-person attendees can register through Ovid's Investor Relations.

Ovid Therapeutics (NASDAQ: OVID) presented results of a pre-clinical study comparing OV329 to vigabatrin (VGB) at the Epilepsy Pipeline Conference. The study found that OV329 did not accumulate in mouse retinas, eyes, or brains after 48 hours of continuous exposure, unlike VGB which showed ocular accumulation. OV329's unique properties, including potency, short half-life, and rapid tissue elimination, suggest a potentially differentiated ocular safety profile.

The study tested OV329 at 5 mg/kg/day versus VGB at 80 mg/kg/day. OV329 concentrations were undetectable in target tissues, while VGB accumulated preferentially in the retina and other tissues. Ovid is currently conducting a Phase 1 trial of OV329 in healthy volunteers, expected to complete in late 2024, evaluating safety and biomarkers for target engagement and clinical effect.

Ovid Therapeutics Inc. (NASDAQ: OVID) has promoted Meg Alexander to President and Chief Operating Officer (COO). This strategic move aims to strengthen the company's leadership and drive future growth in its mission to develop disease-halting neurotherapeutics for rare epilepsies and brain conditions.

Alexander, who joined Ovid in 2020, will oversee operations, R&D, program management, investor relations, commercial strategy, human resources, and corporate affairs. She brings extensive experience in the biopharmaceutical industry, having guided the launch of over 25 medicines and shaped major initiatives for leading companies.

The promotion is part of Ovid's strategy to advance its development pipeline, which includes novel ROCK2 inhibitors, KCC2 direct activators, and a GABA-aminotransferase inhibitor. This leadership change positions Ovid to capitalize on its scientific, development, and deal-making expertise to create value and impact the lives of those with intractable brain disorders.